Medical Studies
eISSN: 2300-6722
ISSN: 1899-1874
Medical Studies/Studia Medyczne
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
4/2025
vol. 41
 
Share:
Send email
Share:
abstract:
Review paper

The impact of tolvaptan on autosomal dominant polycystic kidney disease – literature review

Anna Gruszczyńska
1
,
Krzysztof Kowalik
2
,
Grażyna Dutkiewicz
3
,
Anna Rakoczy
1
,
Andrzej Modrzejewski
2

  1. Department of Forensic Medicine, Pomeranian Medical University, Szczecin, Poland
  2. Clinical Department of General Surgery, Pomeranian Medical University, Szczecin, Poland
  3. Clinic of Nephrology, Transplantology and Internal Diseases, University Clinical Hospital No. 2, Pomeranian Medical University, Szczecin, Poland
Medical Studies 2025; 41 (4): 322–329
DOI: https://doi.org/10.5114/ms.2025.157937
Online publish date: 2025/12/15
View full text Get citation
 
PlumX metrics:
This article presents current data from international literature on the impact of tolvaptan on autosomal dominant polycystic kidney disease (ADPKD). The authors have reviewed the latest clinical research literature. Additionally, the paper discusses the molecular biology of ADPKD and the effects of tolvaptan use on liver and kidney function, and presents the treatment of the described disease in adults and children. Complications of tolvaptan treatment are also briefly discussed.
keywords:

olycystic kidney disease, autosomal dominant inheritance, tolvaptan, treatment, autosomal dominant polycystic kidney disease
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Bentus.